(Q37866811)

24 August 2017

1 reference

title

Solanezumab for Alzheimer's disease (English)

1 reference

24 August 2017

0 references

Hossein Samadi

1

1 reference

24 August 2017

David Sultzer

series ordinal

2

1 reference

24 August 2017

language of work or name

English

0 references

publication date

20 April 2011

1 reference

Expert Opinion on Biological Therapy

24 August 2017

published in

1 reference

24 August 2017

volume

11

1 reference

24 August 2017

issue

6

1 reference

24 August 2017

page(s)

787-798

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.578573

24 August 2017

1 reference

Apolipoprotein E, amyloid, and Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.578573

Cholinesterase inhibitors for patients with Alzheimer's disease: systematic review of randomised clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.578573

Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.578573

Therapies for Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.578573

Efficacy and safety of tarenflurbil in mild to moderate Alzheimer's disease: a randomised phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.578573

Recent developments in Alzheimer's disease therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.578573

Therapeutic intervention for Alzheimer's disease with γ-secretase inhibitors: still a viable option?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.578573

Effect of dimebon on cognition, activities of daily living, behaviour, and global function in patients with mild-to-moderate Alzheimer's disease: a randomised, double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.578573

Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.578573

Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.578573

Intracerebroventricular passive immunization with anti-Abeta antibody in Tg2576.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.578573

Microglial activation facilitates Abeta plaque removal following intracranial anti-Abeta antibody administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.578573

Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.578573

Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.578573

Vaccination Strategies for Alzheimer???s Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.578573

Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.578573

Abeta vaccination effects on plaque pathology in the absence of encephalitis in Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.578573

Long-term effects of Abeta42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.578573

Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.578573

A beta oligomers - a decade of discovery

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.578573

The amyloid hypothesis for Alzheimer's disease: a critical reappraisal

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.578573

Intravenous Immunoglobulins as a Treatment for Alzheimerʼs Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.578573

Intravenous immunoglobulins containing antibodies against beta-amyloid for the treatment of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.578573

Cholinergic dysfunction in a mouse model of Alzheimer disease is reversed by an anti-A beta antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.578573

Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.578573

Immunization reverses memory deficits without reducing brain Abeta burden in Alzheimer's disease model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.578573

Amyloid beta: the alternate hypothesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.578573

Alzheimer disease pathology as a host response

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.578573

Disaggregation of Alzheimer beta-amyloid by site-directed mAb.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.578573

Abeta immunotherapy: intracerebral sequestration of Abeta by an anti-Abeta monoclonal antibody 266 with high affinity to soluble Abeta

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.578573

A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.578573

Safety and changes in plasma and cerebrospinal fluid amyloid beta after a single administration of an amyloid beta monoclonal antibody in subjects with Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.578573

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.578573

Exacerbation of cerebral amyloid angiopathy-associated microhemorrhage in amyloid precursor protein transgenic mice by immunotherapy is dependent on antibody recognition of deposited forms of amyloid beta.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.578573

11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.578573

Factors associated with resistance to dementia despite high Alzheimer disease pathology

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.578573

mAbs: a business perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.578573

Evaluation of the safety and immunogenicity of synthetic A 42 (AN1792) in patients with AD

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.578573

10.1517/14712598.2011.578573

21 January 2018

Identifiers

DOI

1 reference

24 August 2017

1 reference